Shots:

• The P-III (MAESTRO-NAFLD-1) safety study evaluates resmetirom (80/100, qd) vs PBO in a ratio (1:1:1) in 972 patients with NAFLD for 52wks.
• The 1EPs & 2EPs of the study showed that the therapy was safe and well-tolerated at both doses, frequency of serious AEs was similar across treatment arms along with low AEs discontinuation. The therapy also showed a reduction in liver fat as measured by MRI-PDFF and reduced atherogenic lipids, including LDLc, apolipoprotein B, and triglycerides
• Additionally, lipid reductions were greater in the 100mg open-label treatment over 100mg in the double-blind arm & patients were less impacted by COVID-related dose interruptions than double-blind patients

Ref: Globe Newswire | Image: Madrigal